Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 3, 2023
Discovery & Translation
Dimeric IgA targets intracellular oncogenes; plus taRNAs and more
BioCentury’s roundup of translational innovations
BioCentury | May 19, 2023
Discovery & Translation
Targets for severe COVID-19; plus Alzheimer’s resistance case study and more
BioCentury’s roundup of translational news
BioCentury | Mar 16, 2023
Data Byte
Translational spotlight on variant-proofing tech for COVID and beyond
Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Apr 6, 2022
Product Development
Kintor prepping submissions of COVID-19 pill after Phase III readout
Phase III data show Kintor’s repurposed prostate cancer therapy protects against hospitalization or death in COVID-19 patients
BioCentury | Jun 17, 2021
Finance
Biden administration commits more than $3B to COVID-19 antiviral development, pandemic preparedness
The Biden administration is allocating more than $3 billion from American Rescue Plan funding towards its Antiviral Program for Pandemics, a collaboration between federal health agencies to support
BioCentury | Feb 13, 2021
Product Development
ACTIV-2 looks beyond mAb infusions with four new treatment arms
The addition of four new treatment arms spanning diverse mechanisms to NIH’s ACTIV-2 master protocol could give a broader picture of which therapeutic strategies will work in outpatient
BioCentury | Feb 4, 2021
Product Development
Preclinical antiviral strategies for COVID-19: Data Byte
Targets and modalities of non-repurposed therapies for COVID-19
BioCentury | Nov 6, 2020
Targets & Mechanisms
Data Byte: newly identified host factors that regulate ACE2 expression
Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies. ACE2 and TMPRSS2 are the most common host targets
BioCentury | May 9, 2020
Product Development
A guide to COVID-19 vaccine modalities in the clinic
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Items per page:
1 - 10 of 23